Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study.

IF 1.7 4区生物学 Q3 BIOLOGY

Open Life Sciences Pub Date : 2025-09-01 eCollection Date: 2025-01-01 DOI:10.1515/biol-2025-1102

Pengwei Yan, Changzhai Wang, Duixian Tuoligan, Aji Kabinuer, Sheng Li, Xue Song, Huanfeng Zhu

{"title":"Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study.","authors":"Pengwei Yan, Changzhai Wang, Duixian Tuoligan, Aji Kabinuer, Sheng Li, Xue Song, Huanfeng Zhu","doi":"10.1515/biol-2025-1102","DOIUrl":null,"url":null,"abstract":"Brain metastases (BMs) usually occur in the advanced stage of cancers with a poor prognosis. This study aimed to compare the clinical efficacy and effects on cognitive function of immunotherapy combined with whole brain radiotherapy (WBRT) and immunotherapy combined with WBRT plus sequential integrated boost (SEB) in the treatment of multiple BMs. A total of 57 patients diagnosed with BMs were included in Kezhou People's Hospital Affiliated to Nanjing Medical University between 2021 and 2023. Patients were allocated into the WBRT group (n = 27) and the WBRT + SEB group (n = 30) based on whether to receive a boost. The WBRT + SEB group showed a higher complete response rate and objective response rate compared to the WBRT group (26.7 vs 14.8%, 90.0 vs 66.7%) (all P < 0.05). The two groups had a median overall survival (OS) time of 11.2 months (95% confidence interval [CI]: 9.3-13.1) and 9.4 months (95% CI: 6.2-12.6), respectively, with no statistically significant difference (P = 0.176). There was no difference in the levels of mini-mental state examination score at 1, 3, and 6 months, as well as the risk of adverse events, after WBRT between the two groups. In conclusion, SEB may improve the remission rate of lesions but not prolong the OS time. The boost would neither increase serious side effects nor would it aggravate cognitive impairment caused by WBRT.","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"20 1","pages":"20251102"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Life Sciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1515/biol-2025-1102","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Brain metastases (BMs) usually occur in the advanced stage of cancers with a poor prognosis. This study aimed to compare the clinical efficacy and effects on cognitive function of immunotherapy combined with whole brain radiotherapy (WBRT) and immunotherapy combined with WBRT plus sequential integrated boost (SEB) in the treatment of multiple BMs. A total of 57 patients diagnosed with BMs were included in Kezhou People's Hospital Affiliated to Nanjing Medical University between 2021 and 2023. Patients were allocated into the WBRT group (n = 27) and the WBRT + SEB group (n = 30) based on whether to receive a boost. The WBRT + SEB group showed a higher complete response rate and objective response rate compared to the WBRT group (26.7 vs 14.8%, 90.0 vs 66.7%) (all P < 0.05). The two groups had a median overall survival (OS) time of 11.2 months (95% confidence interval [CI]: 9.3-13.1) and 9.4 months (95% CI: 6.2-12.6), respectively, with no statistically significant difference (P = 0.176). There was no difference in the levels of mini-mental state examination score at 1, 3, and 6 months, as well as the risk of adverse events, after WBRT between the two groups. In conclusion, SEB may improve the remission rate of lesions but not prolong the OS time. The boost would neither increase serious side effects nor would it aggravate cognitive impairment caused by WBRT.

Abstract Image

查看原文本刊更多论文

免疫治疗联合全脑放疗对多发性脑转移患者预后的影响：一项回顾性队列研究。

脑转移瘤（BMs）通常发生在预后较差的晚期癌症。本研究旨在比较免疫治疗联合全脑放疗（WBRT）与免疫治疗联合全脑放疗加序贯综合增强（SEB）治疗多发性脑转移的临床疗效及对认知功能的影响。在2021年至2023年期间，南京医科大学附属克州人民医院共纳入了57名被诊断为脑转移的患者。根据是否接受增强治疗，将患者分为WBRT组（n = 27）和WBRT + SEB组（n = 30）。WBRT + SEB组的完全缓解率和客观缓解率均高于WBRT组（26.7% vs 14.8%, 90.0 vs 66.7%）（均P < 0.05）。两组患者的中位总生存期（OS）分别为11.2个月（95%可信区间[CI]: 9.3 ~ 13.1）和9.4个月（95% CI: 6.2 ~ 12.6），差异无统计学意义（P = 0.176）。两组患者在WBRT后1、3、6个月的精神状态测试分数水平及不良事件发生风险均无差异。综上所述，SEB可提高病灶缓解率，但不能延长OS时间。这种刺激既不会增加严重的副作用，也不会加重WBRT引起的认知障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Life Sciences BIOLOGY-

CiteScore

2.50

自引率

4.50%

发文量

131

审稿时长

43 weeks

期刊介绍： Open Life Sciences (previously Central European Journal of Biology) is a fast growing peer-reviewed journal, devoted to scholarly research in all areas of life sciences, such as molecular biology, plant science, biotechnology, cell biology, biochemistry, biophysics, microbiology and virology, ecology, differentiation and development, genetics and many others. Open Life Sciences assures top quality of published data through critical peer review and editorial involvement throughout the whole publication process. Thanks to the Open Access model of publishing, it also offers unrestricted access to published articles for all users.